Interferon in renal cell carcinoma. The UCLA experience

Area of Science:

• Oncology
• Immunotherapy

Background:

• Metastatic renal cell carcinoma (mRCC) has limited treatment options.
• Alpha interferon (IFN-α) has been explored as a therapeutic agent for mRCC.

Purpose of the Study:

• To assess the efficacy and survival outcomes of alpha interferon-based therapies in patients with metastatic renal cell carcinoma.
• To evaluate the impact of combination therapy and dose escalation of interferon alfa-2a.

Main Methods:

• Three sequential studies involving 84 evaluable patients with mRCC.
• Study I: Human leukocyte alpha interferon (IFN-α) 3x10^6 U/day for 12 weeks.
• Study II: IFN-α plus vinblastine.
• Study III: Escalating doses of interferon alfa-2a (3-36x10^6 U/day).

Main Results:

• Overall response rates (CR+PR) were 17% across studies (14%, 14%, 26%).
• Median survival for all patients was 49 weeks.
• Patients with complete response (CR), partial response (PR), or minimal response had a median survival of 72 weeks.
• Favorable prognostic factors (Karnofsky score, disease-free interval, lung-confined disease) correlated with improved survival.

Conclusions:

• Alpha interferon therapy demonstrates activity in metastatic renal cell carcinoma.
• Response to therapy is associated with prolonged survival, though causality requires further investigation.
• Prognostic factors significantly influence survival outcomes in mRCC patients treated with IFN-α.